Ambrx Biopharma Inc. (NYSE: AMAM) is 365.20% higher on its value in year-to-date trading and has touched a low of $0.38 and a high of $13.07 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AMAM stock was last observed hovering at around $10.55 in the last trading session, with the day’s gains setting it 0.01% off its average median price target of $8.50 for the next 12 months. It is also 4.0% off the consensus price target high of $11.00 offered by 3 analysts, but current levels are -76.0% lower than the price target low of $6.00 for the same period.
Currently trading at $10.56, the stock is 59.54% and 175.99% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.35 million and changing 0.09% at the moment leaves the stock 341.92% off its SMA200. AMAM registered 129.32% gain for a year compared to 6-month gain of 751.61%.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
The stock witnessed a 613.51% loss in the last 1 month and extending the period to 3 months gives it a 269.23%, and is 6.13% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 16.36% over the week and 32.27% over the month.
Ambrx Biopharma Inc. (AMAM) has around 81 employees, a market worth around $373.30M and $5.20M in sales. Distance from 52-week low is 2678.95% and -19.20% from its 52-week high. The company has generated returns on investments over the last 12 months (-33.90%).
Ambrx Biopharma Inc. (AMAM) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Ambrx Biopharma Inc. (AMAM) is a “Overweight”. 3 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 1 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Ambrx Biopharma Inc. is expected to release its quarterly report on 05/31/2023.The EPS is expected to shrink by -301.70% this year
Ambrx Biopharma Inc. (AMAM) Top Institutional Holders
The shares outstanding are 38.62M, and float is at 5.52M with Short Float at 30.04%.
Ambrx Biopharma Inc. (AMAM): Who are the competitors?
The company’s main competitors (and peers) include Rogers Corporation (ROG) that is -44.97% lower over the past 12 months. AstraZeneca PLC (AZN) is 6.94% up on the 1-year trading charts.